Technical Analysis for ZGNX - Zogenix, Inc.
|Grade||Last Price||% Change||Price Change|
ZGNX closed down 1.03 percent on Friday, December 14, 2018, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
|Weak or Absent||Down||Flat||Down|
|See historical ZGNX trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 14||Fell Below 20 DMA||Bearish||0.00%|
|Dec 14||Fell Below 50 DMA||Bearish||0.00%|
|Dec 13||20 DMA Support||Bullish||-1.03%|
|Dec 13||50 DMA Support||Bullish||-1.03%|
|Dec 12||NR7||Range Contraction||-5.73%|
|Dec 12||Inside Day||Range Contraction||-5.73%|
|Dec 12||Up 3 Days in a Row||Strength||-5.73%|
|Dec 11||200 DMA Resistance||Bearish||-5.06%|
|Dec 11||Upper Bollinger Band Touch||Strength||-5.06%|
|Dec 10||50 DMA Support||Bullish||-3.81%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ZGNX news...
|52 Week High||62.75|
|52 Week Low||33.42|
|200-Day Moving Average||44.5552|
|50-Day Moving Average||41.6228|
|20-Day Moving Average||41.891|
|10-Day Moving Average||42.845|
|Average True Range||1.9554|
|Chandelier Exit (Long, 3 ATRs )||39.1038|
|Chandelier Exit (Short, 3 ATRs )||44.4362|
|Upper Bollinger Band||44.5577|
|Lower Bollinger Band||39.2243|
|Percent B (%b)||0.42|
|MACD Signal Line||0.1533|
|Market Cap||1.03 Billion|
|Num Shares||24.8 Million|
|Price-to-Earnings (P/E) Ratio||-12.12|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||44.40|
|Resistance 3 (R3)||44.55||43.73||43.90|
|Resistance 2 (R2)||43.73||42.97||43.65||43.74|
|Resistance 1 (R1)||42.58||42.51||42.17||42.43||43.57|
|Support 1 (S1)||40.61||41.00||40.20||40.46||39.31|
|Support 2 (S2)||39.79||40.54||39.71||39.14|
|Support 3 (S3)||38.64||39.79||38.98|
|Support 4 (S4)||38.49|